-
1
-
-
23844434211
-
The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential
-
Chaudhuri KR, Yates L, Martinez-Martin P. The non-motor symptom complex of Parkinson's disease: A comprehensive assessment is essential. Curr Neurol Neurosci Rep 2005;5:275-283.
-
(2005)
Curr Neurol Neurosci Rep
, vol.5
, pp. 275-283
-
-
Chaudhuri, K.R.1
Yates, L.2
Martinez-Martin, P.3
-
2
-
-
33645755812
-
The Parkinson's complex: parkinsonism is just the tip of the iceberg
-
Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
-
(2006)
Ann Neurol
, vol.59
, pp. 591-596
-
-
Langston, J.W.1
-
3
-
-
79551477291
-
Multi-organ autonomic dysfunction in Parkinson disease
-
Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkinsonism Relat Disord 2011;17:77-83.
-
(2011)
Parkinsonism Relat Disord
, vol.17
, pp. 77-83
-
-
Jain, S.1
-
4
-
-
0141741347
-
Parkinson's disease: Mechanisms and models
-
Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron. 2003;39:889-909.
-
(2003)
Neuron.
, vol.39
, pp. 889-909
-
-
Dauer, W.1
Przedborski, S.2
-
5
-
-
0141741347
-
Parkinson's disease: mechanisms and models
-
Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
-
(2003)
Neuron
, vol.39
, pp. 889-909
-
-
Dauer, W.1
Przedborski, S.2
-
6
-
-
0032890731
-
Parkinson disease, the effect of levodopa, and the ELLDOPA trial
-
Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Arch Neurol 1999;56:529-535.
-
(1999)
Arch Neurol
, vol.56
, pp. 529-535
-
-
Fahn, S.1
-
7
-
-
58349122472
-
Why have we failed to achieve neuroprotection in Parkinson's disease?
-
Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2008;64(suppl 2):S101-S110.
-
(2008)
Ann Neurol
, vol.64
, pp. S101-S110
-
-
Olanow, C.W.1
Kieburtz, K.2
Schapira, A.H.3
-
8
-
-
84873478145
-
Trial designs used to study neuroprotective therapy in Parkinson's disease
-
Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord 2013;28:86-95.
-
(2013)
Mov Disord
, vol.28
, pp. 86-95
-
-
Lang, A.E.1
Melamed, E.2
Poewe, W.3
Rascol, O.4
-
9
-
-
84905455009
-
Network modulation following sham surgery in Parkinson's disease
-
Ko JH, Feigin A, Mattis PJ, et al. Network modulation following sham surgery in Parkinson's disease. J Clin Invest 2014;124:3656-3666.
-
(2014)
J Clin Invest
, vol.124
, pp. 3656-3666
-
-
Ko, J.H.1
Feigin, A.2
Mattis, P.J.3
-
10
-
-
19744378296
-
Levodopa and the progression of Parkinson's disease
-
Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
-
(2004)
N Engl J Med
, vol.351
, pp. 2498-2508
-
-
Fahn, S.1
Oakes, D.2
Shoulson, I.3
-
11
-
-
70349456475
-
A double-blind, delayed start trial of rasagiline in Parkinson's disease
-
Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-1278.
-
(2009)
N Engl J Med
, vol.361
, pp. 1268-1278
-
-
Olanow, C.W.1
Rascol, O.2
Hauser, R.3
-
12
-
-
0036906924
-
Design and analysis of two-period studies of potentially disease-modifying treatments
-
McDermott MP, Hall WJ, Oakes D, Eberly S. Design and analysis of two-period studies of potentially disease-modifying treatments. Control Clin Trials 2002;23:635-649
-
(2002)
Control Clin Trials
, vol.23
, pp. 635-649
-
-
McDermott, M.P.1
Hall, W.J.2
Oakes, D.3
Eberly, S.4
-
13
-
-
84919461672
-
Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa
-
Biaggioni J, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, on behalf of Droxidopa 302 Investigators. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65(1):101-107.
-
(2015)
Hypertension
, vol.65
, Issue.1
, pp. 101-107
-
-
Biaggioni, J.1
Freeman, R.2
Mathias, C.J.3
Low, P.4
Hewitt, L.A.5
Kaufmann, H.6
-
14
-
-
84952037843
-
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
-
Tandon, Cucchiaro J, Phillips D, et al. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. J Psychopharmacol 2016;30(1):69-77.
-
(2016)
J Psychopharmacol
, vol.30
, Issue.1
, pp. 69-77
-
-
Tandon1
Cucchiaro, J.2
Phillips, D.3
-
15
-
-
84951325695
-
Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study
-
Findling RL, Chang K, Robb A, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 2015;54:1020-1031.
-
(2015)
J Am Acad Child Adolesc Psychiatry
, vol.54
, pp. 1020-1031
-
-
Findling, R.L.1
Chang, K.2
Robb, A.3
-
16
-
-
0027530638
-
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
-
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;32:176-183.
-
(1993)
N Engl J Med
, vol.32
, pp. 176-183
-
-
-
17
-
-
35148882113
-
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
-
Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
-
(2007)
Neurology
, vol.69
, pp. 1480-1490
-
-
-
18
-
-
0025232430
-
Parkinson's disease
-
Marsden CD. Parkinson's disease. Lancet 1990;335:948-952.
-
(1990)
Lancet
, vol.335
, pp. 948-952
-
-
Marsden, C.D.1
-
19
-
-
4844226577
-
Parkinsonian signs and substantia nigra neuron density in decendents elders without PD
-
Ross GW, Petrovitch H, Abbott RD, et al. Parkinsonian signs and substantia nigra neuron density in decendents elders without PD. Ann Neurol 2004;56:532-539.
-
(2004)
Ann Neurol
, vol.56
, pp. 532-539
-
-
Ross, G.W.1
Petrovitch, H.2
Abbott, R.D.3
-
20
-
-
61949280270
-
Disease-modification” trials in Parkinson disease: target populations, endpoints and study design
-
Rascol O, “Disease-modification” trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009;72(7 Suppl):S51-S58.
-
(2009)
Neurology
, vol.72
, Issue.7
, pp. S51-S58
-
-
Rascol, O.1
-
21
-
-
84932106482
-
Rational drug discovery design approaches for treating Parkinson's disease
-
Van der Schyf CJ., Rational drug discovery design approaches for treating Parkinson's disease, Expert Opin Drug Discov 2015;10(7):713-741.
-
(2015)
Expert Opin Drug Discov
, vol.10
, Issue.7
, pp. 713-741
-
-
Van der Schyf, C.J.1
-
22
-
-
84994744856
-
Challenges in detecting disease modification in Parkinson's disease clinical trials
-
Athauda D, Foltynie T. Challenges in detecting disease modification in Parkinson's disease clinical trials. Parkinsonism Relat Disord 2016;32:1-11.
-
(2016)
Parkinsonism Relat Disord
, vol.32
, pp. 1-11
-
-
Athauda, D.1
Foltynie, T.2
-
23
-
-
61449173973
-
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design
-
Olanow CW., Hauser RA., Jankovic J., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design. Mov Disord 2008;23:2194-2201.
-
(2008)
Mov Disord
, vol.23
, pp. 2194-2201
-
-
Olanow, C.W.1
Hauser, R.A.2
Jankovic, J.3
-
24
-
-
84969915674
-
Magnetic resonance imaging as a potential biomarker for Parkinson's disease
-
Tuite P. Magnetic resonance imaging as a potential biomarker for Parkinson's disease. Transl Res 2016:175:4-16.
-
(2016)
Transl Res
, vol.175
, pp. 4-16
-
-
Tuite, P.1
-
25
-
-
84962860757
-
Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson's disease stages?
-
Hopes L, Grolez G, Moreau C, et al. Magnetic resonance imaging features of the nigrostriatal system: biomarkers of Parkinson's disease stages? PLoS One 2016;11:e0147947.
-
(2016)
PLoS One
, vol.11
-
-
Hopes, L.1
Grolez, G.2
Moreau, C.3
-
26
-
-
84897930725
-
Targeting chelatable iron as a therapeutic modality in Parkinson's disease
-
Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014;10;21(2):195-210.
-
(2014)
Antioxid Redox Signal
, vol.10
, Issue.2
, pp. 195-210
-
-
Devos, D.1
Moreau, C.2
Devedjian, J.C.3
-
27
-
-
84861325008
-
New developments of dopaminergic imaging in Parkinson's disease
-
Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging 2012;56:68-82.
-
(2012)
Q J Nucl Med Mol Imaging
, vol.56
, pp. 68-82
-
-
Varrone, A.1
Halldin, C.2
-
28
-
-
73049095463
-
Neuroprotection and imaging studies in Parkinson's disease
-
Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl 4):S33-S37.
-
(2009)
Parkinsonism Relat Disord
, vol.15
, pp. S33-S37
-
-
Pavese, N.1
Kiferle, L.2
Piccini, P.3
-
29
-
-
84904126994
-
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
-
References for the Supplementary Material
-
Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 2014;4(3):337-344. References for the Supplementary Material
-
(2014)
J Parkinsons Dis
, vol.4
, Issue.3
, pp. 337-344
-
-
Aviles-Olmos, I.1
Dickson, J.2
Kefalopoulou, Z.3
|